Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
PortrAIt: Artificial intelligence for cancer diagnosis and therapy
Launched on March 31st in Villejuif, PortrAIt is a consortium resulting from the collaboration between Gustave Roussy and the start-up Owkin, incorporating key players in oncology. Its goal is to develop and deploy nationally around fifteen artificial intelligence tools in digital pathology to improve cancer management. This project aims to make France a global leader in personalized medicine based on artificial intelligence in the next five years.
Published on
Launched on March 31st in Villejuif, PortrAIt is a consortium resulting from the collaboration between Gustave Roussy and the start-up Owkin, incorporating key players in oncology. Its goal is to develop and deploy nationally around fifteen artificial intelligence tools in digital pathology to improve cancer management. This project aims to make France a global leader in personalized medicine based on artificial intelligence in the next five years.
Financed by the France 2030 investment plan and implemented by the agency Bpifrance, PortrAIt is a new consortium bringing together Gustave Roussy and Owkin, the Leon Berard cancer center, the French digital imaging company Tribun Health, the French pathological diagnosis company Cypath, and the National Federation of French Cancer Centers (Unicancer).
Structuring and organizing innovative artificial intelligence solutions
This ambitious project is based on the creation of 15 artificial intelligence tools for digital pathology diagnosis and therapy. The formation of machine learning models (deep learning) should allow the analysis of data from digital pathology slides (digitized images of patient tissue samples) for the development of more effective and accessible diagnostic tools, thus helping oncologists to personalize treatments at an earlier stage of the disease. PortrAIt will also accelerate the work of pathologists to detect the presence of certain biomarkers or predict patient outcomes. All these digital tools will be brought together on an evolving and interoperable digital platform that offers a research and collaboration framework for PortrAIt partners to be tested and deployed in French cancer centers and laboratoriesIn 2019, a framework agreement for research partnership and long-term collaboration was signed between Gustave Roussy and Owkin. This led to the development of RelaspRisk BC, the first prognostic artificial intelligence solution based on digital pathology, which predicts the risk of relapse in patients with localized breast cancer to avoid unnecessary chemotherapy after surgery.
Last news
-
Breast Cancer: Gustave Roussy Ranked No. 1 in France for Breast Surgery and Breast Reconstruction
On the occasion of Breast Cancer Awareness Month, the 2025 data from Visuchir, the national surgical activity monitoring tool of the French Health Insurance system, places Gustave Roussy in first position for both breast surgery and breast reconstruction. Beyond this ranking, these figures highlight that reconstruction is now an integral part of breast cancer treatment. It is considered at every stage of care: from tumor removal surgery, whether lumpectomy or mastectomy, through to the post-cancer period, helping to restore the body and support women in regaining their physical integrity and quality of life.
-
Newsweek Ranking: Gustave Roussy Named Europe’s Leading Cancer Centre and Third Best Worldwide
The 2027 edition of Newsweek’s World's Best Specialized Hospitals ranking once again recognises Gustave Roussy as the leading cancer centre in France and Europe, and the third best worldwide. This distinction highlights the excellence of the Institute’s care and research, as well as the daily commitment of all its professionals.
-
Living with and beyond cancer: the promises and challenges of digital health
In a Viewpoint article published in The Lancet Digital Health, Drs Ines Vaz-Luis and Maria Alice Franzoi, together with Emmanuel Mussault, a patient partner at the PRISM University Hospital Institute, examine the role that digital tools can play in supporting people living with and beyond cancer. Their central message is that these technologies can support more personalised and accessible care, but their value depends primarily on how they are integrated into care pathways, the human support provided, their ability to address individual needs and their evaluation in real-world settings.
-
Gustave Roussy and The Lancet launch an international lecture series on innovations transforming cancer care
The inaugural lecture in the “Lecture Series on Cancer Breakthroughs” will take place on Friday 18 September at 5:00 pm. It will be delivered by Professor Timothy R. Rebbeck, a leading cancer prevention specialist at Harvard University and the Dana-Farber Cancer Institute.
